GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous Treatment
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of GDC-0449 in treating young
patients with medulloblastoma that is recurrent or did not respond to previous treatment.
GDC-0449 may be effective in treating young patients with medulloblastoma.